USFDA rules against Sun Pharma Advanced Research Co's appeal regarding cancer drug application

The Office of New Drugs (OND) of the US Food and Drug Administration (FDA) has denied the company's appeal of the Complete Response Letter (CRL) in relation to the New Drug Application (NDA) for Taclantis, Sun Pharma Advanced Research Company (SPARC) said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news